[
    " with CH<sub>3</sub>I and K<sub>2</sub>CO<sub>3</sub>, AcCl and K<sub>2</sub>CO<sub>3</sub>, or BnBr and K<sub>2</sub>CO<sub>3</sub>. The protecting group, X, may comprise tert-butyl silane. </p>[0028] In yet another embodiment, a method is provided for preparing a psorospermin analog having a formula:  \n<img id=\"EMI-C00013\" path=\"US20030120093A1-20030626-C00013.TIF\" file=\"https://surechembl.org/api/assets/attachment/23875929/US/20030626/A1/020030/12/00/93/US20030120093A1-20030626-C00013.TIF\"/>\n</p>[0029] wherein R is a hydrogen, an alkyl, a hydroxyl, a hydroxyalkyl, a halogen, a benzyl, an amine, an alkylamine, a thiol, or an alkylthiol. The method comprises obtaining a first compound having a formula:  \n<img id=\"EMI-C00014\" path=\"US20030120093A1-20030626-C00014.TIF\" file=\"https://surechembl.org/api/assets/attachment/23875817/US/20030626/A1/020030/12/00/93/US20030120093A1-20030626-C00014.TIF\"/>\n</p>[0030] performing a reaction to remove the CH<sub>3 </sub>group from the oxygen at the 1 position, performing a chemical reaction with an alkylating agent and a base, and performing an epoxidation or an epoxide forming reaction. In one embodiment, the performing a reaction to remove the CH<sub>3 </sub>group from the oxygen at the 1 position may comprise performing a chemical reaction using BCl<sub>3</sub>. The performing a chemical reaction with an alkylating agent and a base may comprise performing a chemical reaction with EtI and Cs<sub>2</sub>CO<sub>3</sub>, isopropyl bromide, KI, Cs<sub>2</sub>CO<sub>3</sub>, AcCl and K<sub>2</sub>CO<sub>3</sub>, or BnBr and K<sub>2</sub>CO<sub>3</sub>. </p>[0031] A method of inhibiting cell proliferation is also provided. The method comprises contacting a cell with an effective amount of a compound having the following formula:  \n<img id=\"EMI-C00015\" path=\"US20030120093A1-20030626-C00015.TIF\" file=\"https://surechembl.org/api/assets/attachment/23875971/US/20030626/A1/020030/12/00/93/US20030120093A1-20030626-C00015.TIF\"/>\n</p>[0032] wherein R<sub>1 </sub>and R<sub>2 </sub>are independently hydrogen, a benzyl, an alkyl, an acetyl, a hydroxyl, a hydroxyalkyl, a halogen, an amine, an alkylamine, a thiol, or an alkylthiol. The cell may be a cancer cell, and more particularly may be a pancreatic cancer cell, a prostate cancer cell, a leukemias cell, a lymphomas cell, a myeloma cell, an ovarian cancer cell, or a breast cancer cell. The cancer cell may also be a multi-drug resistant (MDR) cancer cell. The MDR cancer cell may be resistant to a topoisomerase II inhibitor and may be mediated by MRP-1 or glycoprotein. The cell may also be in a mammal. </p>[0033] A method is also provided for directing the sequence-specific alkylation of DNA. The method comprises contacting a cell with an effective amount of a compound having the following formula:  \n<img id=\"EMI-C00016\" path=\"US20030120093A1-20030626-C00016.TIF\" file=\"https://surechembl.org/api/assets/attachment/23875889/US/20030626/A1/020030/12/00/93/US20030120093A1-20030626",
    "Cl<sub>2 </sub>(300 mL). The organic layers were combined, washed with brine (400 mL), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to provide a red sludge which could be tritrated with EtOH and filtered to afford (9.3 g, 66%) of (103) as a pink solid. Analytically pure material can be obtained at this point by column chromatography with 50% EtOH/hexane. (LH-63-5) <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>) \u03b4 7.84 (d, 1 H, J=6.0 Hz), 7.42\u22127.31 (complex, 5 H), 7.20\u22127.07 (complex, 2 H), 6.63 (s, 1 H), 6.37 (s, 1 H), 5.08 (s, 2 H), 3.92 (s, 3 H), 3.88 (s, 3 H); <sup>13</sup>C NMR (62.5 MHz) \u03b4 175.2, 163.8, 161.7, 159.4, 147.8, 144.5, 135.6, 128.6, 128.3, 127.5, 123.9, 123.1, 117.5, 114.3, 106.1, 95.9, 93.6, 70.4, 56.3, 56.2; mass spectrum (CI) m/z+1 363.1242 [C<sub>22</sub>H,<sub>19</sub>O<sub>5 </sub>(M+1) requires 363.1232] 363 (base), 339. </p>[0310] 1,5-Dimethoxy-3-(3\u20323\u2032-dimethylpropynoxy) xanthone (104). FeCl<sub>3 </sub>(9.0 g, 69 mmol) was added in portions to (103) (5.0 g, 17 mmol) in CH<sub>2</sub>Cl<sub>2 </sub>(150 mL). After stirring for 40 min, H<sub>2</sub>O was added (300 mL) and the reaction stirred/swirled vigorously. The reaction was filtered through a very large buchner funnel, and the brown ppt was washed with H<sub>2</sub>O (300 mL) and ether (200 mL) and dried overnight on the funnel. </p>[0311] To the crude dimethyl ether xanthone (3.27 g, 12.0 mmol) in DMF (60 mL) was added 3-chloro-3-methyl-1-butyne (11.8 g, 36.1 mmol), KI (1.0 g, 6.01 mmol) and Cs<sub>2</sub>CO<sub>3 </sub>(11.8 g, 36.1 mmol). The reaction was heated at 50\u00b0 C. for 19h, cooled to rt, and then placed in an ice-bath. 2M HCl was added until the reaction had been quenched and no more foaming was observed. The mixture was then diluted with CH<sub>2</sub>Cl<sub>2 </sub>(200 mL) and the layers were separated. The organic layer was washed with sat. NaCl (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. The crude product was purified by column chromatography (60% EtOAc/hex) to yield 3.50 g (75%) of a yellow solid. (LH-63-16) <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>) \u03b4 7.88 (d,1 H, J=5.12 Hz), 7.20\u22127.02 (m, 3 H), 4.00 (s, 3 H), 3.98 (s, 3 H), 2.78 (s, 1 H), 1.80 (s, 6 H; <sup>13</sup>C NMR (62.5 MHz) \u03b4 175.1, 161.4, 161.2, 158.7, 147.8, 145.2, 123.1, 117.6, 115.5, 114.5, 107.6, 98.7, 98.6, 84.6, 76.9, 72.6, 56.2, 29.4; mass spectrum (CI) m/z+1 339.1233 [C<sub>20</sub>H<sub>19</sub>O<sub>5 </sub>(M+1) requires 339.1232] 339 (base), 273. </p>[0312] 1,5-Dimethoxy-3-(3\u20323\u2032-dimethylpropenoxy) xanthone (105). 5% Pd/CaCO<sub>3 </sub>poisoned with lead (Lindlar's catalyst) (1.37 g, 0.642 mmol) was added to a solution of (104) (2.17 g, 6.42 mmol) and quinoline (3.5 mL) in benzene (200 mL). The reaction flask was evacuated, and then backfilled with H<sub>2 </sub>from a balloon. The reaction was stirred under H<sub>2 </sub>for 2 h. (The reaction can be monitored by the <sup>1</sup>HNMR of small aliquots w"
]